Health Care·Biotechnology·$5.7B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-2.35 | N/A | -19.84% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-2.35 | N/A | -19.84% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced in the quarter. They emphasized their commitment to long-term goals without offering specific future guidance.
Management did not provide specific guidance for future quarters.
The company is focusing on its strategic initiatives despite the current challenges.
PTC Therapeutics reported a wider-than-expected loss per share, which contributed to a 4.2% decline in its stock price. The lack of revenue details and future guidance may raise concerns among investors about the company's short-term performance. The management's defensive tone suggests they are navigating challenges but remain focused on long-term strategies.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
PHOTRONICS INC
Feb 20, 2023